INTRODUCTION
Innate immunity is the first line of defense directed against components common to microorganisms (1, 2) . One of the antimicrobial mechanisms of innate immunity in insects is the prophenoloxidase cascade, which is present in hemolymph and cuticle (3) . The prophenoloxidase cascade can be initiated by the binding of a 19 kDa protein, peptidoglycan-recognition protein 6 described before (22) . Purified smooth LPS, obtained from Escherichia coli O113 by phenolwater extraction (refined endotoxin standard, approximate average M r = 15,000) was obtained from Ribi Immunochem Research (Hamilton, MT).
Recombinant human full-length (residues 1-323) soluble CD14 and recombinant human 1-152 CD14 N-terminal fragment were the same as before (13) Human peripheral blood, obtained from healthy males (24-49 years old of Caucasian, Asian, or African-American origin) was separated by centrifugation through two Histopaque layers (density 1.077 g/ml and 1.119 g/ml, Sigma) into PBMC and into PMNs (98% pure as determined by morphology on Wright-stained smears). Monocytes were isolated from PBMC by adherence to plastic (25, 26), and were >95% pure as judged by morphology on Wright-stained smears, phagocytosis of Latex, and non-specific esterase, and did not contain any detectable PMNs glycerol, 1% NP-40, and a cocktail of protease inhibitors), boiled with PAGE sample buffer (2% SDS and 1% 2-mercaptoethanol), centrifuged at 12,000xg, and the supernatants were subjected to 12% SDS-PAGE, blotted onto PVDF membrane (Immobilon P, Millipore), and the membranes were blocked with 5% milk (17) . The membranes were incubated with rabbit anti-PGRP serum Assays for PGN-lytic, bacteriolytic, and bacteriostatic activities. To test if PGPR had any PGN-lytic activity, biotin-labeled sPGN (13) (50 µg/ml in 10 mM HEPES, pH 7.0, with 0.85% NaCl, and with or without 1 mM ZnSO 4 ) was incubated for 24 h at 37 o C without or with PGRP or control PGN-lytic enzymes (lysozyme or lysostaphin) at 0.1 to 100 µg/ml as described (13) . The digests were subjected to SDS-PAGE, blotted onto Immobilon, and biotin-sPGN was detected with streptavidin-peroxidase and enhanced chemiluminescence as described (13 The ranges of phagocytic index without PGRP for Micrococcus and latex were 250-600 and 400-700, respectively. Serum was included in the medium because it was required for phagocytosis of bacteria, which were not phagocytized in the absence of serum, regardless of the presence of PGRP.
Similar results were obtained with mouse serum and fetal bovine serum. (17) with medium alone (Nil), or with 0.1, 1, or 10 µg/ml sPGN, or 0.1 µg/ml (serum-free conditions) or 0.01 µg/ml (medium with serum) ReLPS, without or with 1 or 10 µg/ml PGRP. The culture supernatants were collected after 6 h of stimulation at 37 o C/5% CO 2 , and assayed for TNF-α concentrations using the L929 cytotoxicity assay (17) described below, or for IL-6 using the IL-6-dependent 7DT1 cells as before (25).
Oxidative burst (NBT test

Cytotoxicity for mammalian cells. To test if PGRP has any TNF-like cytotoxic activity, we
used the standard L929 cell cytotoxicity assay that is commonly used for measuring cytotoxic activity of TNF, performed as described (17) . Briefly, medium alone or serial double dilutions of PGRP alone (20 pg/ml to 10 µg/ml), or recombinant mouse TNF-α standard alone (specific activity, 4 x 10was measured spectrophotometrically after staining with crystal violet, and a standard curve for TNF-α cytotoxicity was fitted into a sigmoidal equation as before (17) .
Chemotaxis. Chemotaxis was evaluated as described (34). Medium alone (RPMI-1640
with 10 mM HEPES, pH 7.2, and 1 mg/ml or 10 mg/ml BSA), sPGN alone, PGRP alone, or sPGN and PGRP together (at 0.001 to 1 µg/ml), or control chemoattractants, 0.1 nM fromyl-methylleucyl-methionine (fMLP, Sigma), 20 ng/ml of monocyte chemoattractant protein-1 (MCP-1, sp.
act. 1000 U/µg), or 200 ng/ml of GRO-α (sp. act. 100,000 U/µg, both human recombinant proteins aureus, are, in contrast to S. aureus, also highly sensitive to lysozyme, because they have non-Oacetylated PGN (36). Therefore, all these data together suggest that PGRP has a similar specificity to lysozyme, but 200 to 300 times higher affinity (37).
Native mouse PGRP had a similar binding potential as the recombinant PGRP, as shown by similar binding of virtually all native PGRP from the lysates of mouse bone marrow cells and recombinant PGRP to sPGN-agarose and Micrococcus, and no binding of either PGRP to control agarose or latex particles, as detected by Western blotting (Fig. 6 ). These results confirm that the recombinant PGRP has the proper conformation for the binding to PGN and bacteria, and that the C-terminal 6xHis tag present in the recombinant PGRP has no major influence on the binding of PGRP to PGN and bacteria.
PGRP is selectively expressed in polymorphonuclear leukocytes
Previously, high expression of PGRP mRNA was found in the bone marrow (5), and much lower expression was found in the spleen and other organs with high content of immune cells, such as lungs, intestine, and blood (5, 19) , suggesting that PGRP may play a role in immunity. To gain some insight into the function of PGRP, our next experiments were performed to identify the cell type(s) that express PGRP mRNA and PGRP protein.
Using RT-PCR we demonstrated that in the mouse, PGRP mRNA was highly expressed in PMNs and in bone marrow cells (Fig. 7A ). PGRP mRNA was very weakly expressed in spleen cells and peripheral blood mononuclear cells (PBMC), and was not expressed in thymocytes, B and T lymphocytes, and peritoneal macrophages (Fig. 7A) . PGRP mRNA was not expressed in any of the mouse cell lines (B cell, T cell, and macrophages, data not shown), when the same number of PCR cycles was run that revealed high expression of PGRP mRNA in neutrophils and bone marrow (Fig. 7A) . However, when the number of PCR cycles was increased from 20 to 48, PGRP mRNA was expressed to various extent in 3 out of 4 mouse B-lymphocyte cell lines, whereas, even after 48 PCR cycles expression of PGRP mRNA was still not detectable in two T-lymphocyte, three macrophage, one pre-B-lymphocyte, and one plasma cell (hybridoma) cell lines (Fig. 7B ).
This low level expression of PGRP mRNA in B cell tumors is not surprising, because Tag7
(identical to PGRP) was expressed in some tumors and was cloned from a tumor cell line (19) . In humans, PGRP mRNA was also strongly expressed in PMNs, and was not expressed in PBMC, monocytes, B lymphocytes, T lymphocytes, and NK cells (Fig. 7C) . PGRP mRNA was also not expressed in human T-lymphocyte (MOLT-4), B-lymphocyte (RAJI), and monocytic (U-937 and THP-1) cell lines (Fig. 7C) . 
PGRP is not a PGN-lytic enzyme, but it inhibits growth of Gram-positive bacteria
We next tested whether mammalian PGRP had a PGN-lytic or bacteriolytic activity because of three reasons. First, because PGRP sequence has some homology to the T3 and T7
bacteriophage lysozymes (5), which are amidases (i.e., they hydrolyze the bond between muramic acid and the peptide, unlike the vertebrate lysozyme, which is a muramidase, i.e., it hydrolyzes the glycosidic bond between GlcNAc and MurNAc of the glycan chain). Second, because binding specificity of PGRP to PGN is similar to vertebrate lysozyme. And third, because PGRP is expressed in PMNs, and one of the functions of PMNs is digestion of phagocytized bacteria.
However, mouse PGRP that bound to PGN with nanomolar affinity did not have any detectable PGN-lytic activity even at 100 µg/ml, when incubated for 48 h at 37 o C. By contrast, under the same conditions, complete lysis of sPGN with control enzymes, lysozyme and lysostaphin (determined by Western blots), was detectable at 0.5 µg/ml of lysozyme and 5 µg/ml of lysostaphin, and 50% digestion was detectable at 0.05 µg/ml and 0.5 µg/ml, respectively.
PGRP also had no detectable bacteriolytic activity for M. luteus at concentrations up to 25 µg/ml when incubated for up to 24 h. By contrast, lysozyme caused virtually complete lysis of the bacteria (reduction of OD 540 from 0.75 to 0.05) in 30 min at 10 µg/ml and in 90 min at 1 µg/ml of lysozyme.
We next considered the possibility that PGRP may have an antibacterial effect (bacteriostatic or bactericidal), because PGRP is present at high concentrations in PMNs, and because the main function of PMNs is phagocytosis and killing of bacteria. Indeed, PGRP significantly inhibited the growth of Gram-positive bacteria (S. hemolyticus and B. megaterium, Fig. 9 B-D, and also S. warneri and S. capitis, not shown), but had no effect on the growth rate of Gram-negative bacteria (E. coli, Fig. 9A , and also E. cloacae, not shown). PGRP by itself, however, was not bactericidal, and it only inhibited the growth rate of bacteria by about 50%, i.e., it took approximately twice as long to generate similar numbers of bacteria in the cultures with PGRP compared to cultures without PGRP (Fig. 9D and data not shown). Upon prolonged incubation, both cultures eventually reached similar numbers of bacteria ( Fig. 9D and data not shown).
PGRP inhibits phagocytosis and oxidative burst in leukocytes
We next tested the effect of PGRP on phagocytosis of bacteria and on bacterially-induced oxidative burst in leukocytes, because PGRP could be present in serum at low concentrations and/or it could be released from PMNs at the inflammatory sites (the concentration of PGRP in mouse serum was lower than 5 µg/ml, determined on Western blots (Fig. 10A) , and the inhibition was dose-dependent (not shown).
PGRP also inhibited oxidative burst in human PMNs generated by PGRP-binding bacteria (Micrococcus and Bacillus), but it did not inhibit generation of oxidative burst by PGRP-nonbinding bacteria (E. coli) and other PGRP-non-binding stimuli (LPS, or PDB + ionomycin) (Fig. 10B). This inhibition was also dose-dependent (not shown).
PGRP inhibits cytokine induction in macrophages
Because bacteria and their PGN component are potent inducers of cytokine production in macrophages (8, 9), we next considered a possibility that PGRP might have an effect on the macrophage activation by PGN and bacteria. This effect could be either inhibitory, by analogy to the LPS-binding bactericidal permeability-inducing protein (BPI), a protein present in neutrophils (40, 41), or enhancing, by analogy to LBP, an acute-phase protein present in plasma (38, 39).
First, we evaluated the effect of PGRP on the induction of TNF-α and IL-6 production by a mouse macrophage cell line, RAW264.7, adapted to growth in serum-free medium. Serum-free conditions were selected to avoid any possible interference of the native PGRP that could be present at low concentration in the serum. PGRP, at 10 µg/ml, inhibited sPGN-induced TNF-α and IL-6
production by 62% and 80%, respectively, but did not significantly inhibit ReLPS-induced production of TNF-α and IL-6 ( Fig. 11) . At 1 µg/ml, PGRP still inhibited sPGN-induced production of IL-6 by 65%, but it did not significantly inhibit the production of TNF-α (not shown).
Next we tested the influence of serum on the effect of PGRP on the sPGN-induced cytokine production, because serum could contain other components that could either enhance or inhibit the effect of PGRP. The sPGN-and ReLPS-induced production of TNF-α and IL-6 in RAW264.7 cells cultured in the presence of 10% serum was not significantly changed by the presence of 1 or 10 µg/ml of PGRP, thus demonstrating that serum abolished the inhibitory effect of PGRP on sPGN-induced cytokine production. This may be due to the already diminished responses of cells to sPGN in the presence of serum that we have observed before (14) , although the components in the serum responsible for this decreased responsiveness to sPGN are still unknown.
PGRP has no TNF-like cytotoxicity
We next tested whether PGRP was cytotoxic for tumor cell lines, because it was suggested that Tag7, which has identical sequence to PGRP (5), is a new cytokine with a TNF-like cytotoxicity (19) . However, none of our mouse PGRP preparations (which all bound PGN with nanomolar affinity, see above), at 20 pg/ml to 10 µg/ml, had any cytotoxicity for L929 cells under the conditions at which TNF-α induced 50% cytotoxicity at 10 pg/ml and 95% cytotoxicity at 100 pg/ml, as evaluated microscopically and measured spectrophotometrically (Fig. 12 ). Moreover, PGRP had no effect on TNF-α-induced cytotoxicity for L929 cells (Fig. 12) , and it also was not cytotoxic for three other tumor cell lines and for primary cells (mouse and human leukocytes, human fibroblasts, and primary human endothelial cells). This lack of PGRP cytotoxicity was confirmed independently in two laboratories.
PGRP and PGRP:sPGN complexes are not chemotactic
Because chemotaxis and production of chemotactic chemokines are the most prominent host responses to bacteria and bacterial products, including PGN (18), we also tested if PGRP by itself or in combination with sPGN had any chemotactic activity. However, neither PGRP nor sPGN by themselves or together (at 0.001 to 1 µg/ml) were chemotactic for human monocytes or given all these differences in the specificities and functions of PGRP and CD14, it is not surprising that they do not share any structural or sequence homology. PGRP also has no structural and sequence homology to TLR2, another pattern-recognition receptor that recognizes PGN (14-16).
The binding specificity of PGRP is similar to the specificity of lysozyme (43). We have confirmed that mouse PGRP (5) and Tag7 (19) is the same protein, because they have the same cDNA sequence (5, 19) and gene sequence (19 and 4 ). However, two aspects of our results on the expression and function of PGRP differ from the results reported for Tag7 (19) .
First, we found that PGRP is primarily expressed in neutrophils, is only very weakly expressed in spleen cells, and is not expressed in purified macrophages, T and B lymphocytes, and NK cells, that are free of neutrophils. Tag7 mRNA was shown to be present in peritoneal macrophages, spleen, and lung (19) , however, its presence in neutrophils or highly purified lymphocyte subpopulations was not studied (19) . We have found that contamination of tissues with blood-derived neutrophils makes these tissues positive on PGRP mRNA expression tests, which could be one possible explanation of the positive results of Tag7 expression in peritoneal macrophages, spleen, and lung (19) . Also, in contrast to the results reported for Tag7 (19), we could not detect any increase in PGRP expression in lymphocytes or macrophages following stimulation with PGN, LPS, or bacteria. Thus, our current results are consistent with previously reported (5) very high expression of PGRP in the bone marrow (the site of neutrophil production and of the neutrophil bone marrow reserve pool), and very low expression in other lymphoid tissues, that might have been due to contamination of these tissues with blood. This interpretation is consistent with the expression of Tag7, that could only be detected in freshly isolated spleen cells, but not in B and T lymphocytic cell lines (19) . It is also possible, however, that some other cells than neutrophils express very low levels of PGRP mRNA and do not express, or express only very low levels of PGRP protein (undetectable by Western Blot).
Second, in contrast to Tag7 (19) , our PGRP has no TNF-like cytotoxicity for L929 cells and other tumor cell lines, even at concentrations of PGRP 10 5 times higher than the cytotoxic concentrations of TNF-α. The reason for this discrepancy is unclear, although it may be related to the fact that we have used purified PGRP protein, whereas previously crude culture supernatants containing Tag7, rather than purified Tag7 protein, were tested (19) . Therefore, our results firmly establish PGRP as a peptidoglycan binding protein that interacts with bacteria and has no TNF-like cytotoxicity. Also consistent with PGN-binding activity of PGRP and its expression in neutrophils is our finding that PGRP inhibits growth of Gram-positive bacteria in vitro.
PGRP also has no effect on the cytotoxicity of TNF-α, but it inhibits some of the (B) The Scatchard plot was fitted using Cricket Graph software, and mean apparent dissociation constants (K d ) ± SE were calculated using curve fitting to a hyperbolic function (SigmaPlot software). The results are means of 4 samples from 2 experiments; in (B), the SE were less than 15% and are not shown. by guest on July 16, 2017 
